CAROLINE INGE: Open Payments
NPI 1538791074 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$671 in 28 payments from 13 companies in 2025. Trend: 2023 $14 · 2024 $190 · 2025 $671
Food & beverage: $671
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $129 |
| Merck Sharp & Dohme LLC | 5 | $120 |
| Incyte Corporation | 4 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| Janssen Biotech, Inc. | 3 | $61 |
| JAZZ PHARMACEUTICALS INC. | 1 | $35 |
| Exelixis Inc. | 1 | $30 |
| Monteris Medical Corporation | 1 | $24 |
| Aveo Pharmaceuticals, Inc. | 1 | $23 |
| TerSera Therapeutics LLC | 1 | $22 |
Products named: IMFINZI, KEYTRUDA, FRUZAQLA, MONJUVI, RYBREVANT, CABOMETYX, JAKAFI, PEMAZYRE.
Industry payments across AL — which companies pay providers there.
